Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Franck

Showing results (101-110 of 125) with videos related to

Pageof 13
Sort By:
Alcoholism, Clinical and Experimental Research|October 28, 2015
Phosphatidylethanol is superior to carbohydrate-deficient transferrin and γ-glutamyltransferase as an alcohol marker and is a reliable estimate of alcohol consumption levelLisa Walther, Andrea de Bejczy, Elin Löf, et al.
The Lancet Regional Health. Europe|June 9, 2025
Efficacy and safety of varenicline and bupropion, in combination and alone, for alcohol use disorder: a randomized, double-blind, placebo-controlled multicentre trialBo Söderpalm, Helga Lidö, Johan Franck, et al.
JAMA Pediatrics|August 16, 2020
Association of Opioid Prescription Initiation During Adolescence and Young Adulthood With Subsequent Substance-Related MorbidityPatrick D Quinn, Kimberly L Fine, Martin E Rickert, et al.
Pediatrics|February 7, 2022
Initiation of Opioid Prescription and Risk of Suicidal Behavior Among Youth and Young AdultsKimberly L Fine, Martin E Rickert, Lauren M O'Reilly, et al.
European Addiction Research|March 7, 2018
International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity DisorderCleo L Crunelle, Wim van den Brink, Franz Moggi, et al.
Psychiatria Hungarica : a Magyar Pszichiatriai Tarsasag Tudomanyos Folyoirata|December 2, 2020
[Recommendations for the screening, diagnosis and treatment of patients with comorbid attention deficit hyperactivity- and substance use disorder]Máté Kapitány-Fövény, Csaba Barta, Cleo L Crunelle, et al.
European Addiction Research|June 30, 2020
The International Collaboration on ADHD and Substance Abuse (ICASA): Mission, Results, and Future ActivitiesGeurt Van de Glind, Christoffer Brynte, Arvid Skutle, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 28, 2026
Polygenic risk scores reveal genetic underpinnings of comorbidity betweensubstance use disorders and ADHDLisa I Horstman, Dora Koller, Judit Cabana-Domínguez, et al.
The International Journal of Social Psychiatry|June 13, 2025
Religiousness and self-control in patients with substance use disorder (SUD) and comorbid attention deficit/hyperactivity disorder (ADHD)Alex Ha Begeman, Arnt Schellekens, Wim van den Brink, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 7, 2026
Predictors of treatment success in patients with substance use disorder (SUD) and co-morbid attention deficit/hyperactivity disorder (ADHD): Results from the International Naturalistic Cohort Study of ADHD and SUD (INCAS)Christoffer Brynte, Arnt Schellekens, Maija Konstenius, et al.
Pageof 13

Showing results (101-110 of 125) with videos related to

Sort By:
Pageof 13
Alcoholism, Clinical and Experimental Research|October 28, 2015
Phosphatidylethanol is superior to carbohydrate-deficient transferrin and γ-glutamyltransferase as an alcohol marker and is a reliable estimate of alcohol consumption levelLisa Walther, Andrea de Bejczy, Elin Löf, et al.
The Lancet Regional Health. Europe|June 9, 2025
Efficacy and safety of varenicline and bupropion, in combination and alone, for alcohol use disorder: a randomized, double-blind, placebo-controlled multicentre trialBo Söderpalm, Helga Lidö, Johan Franck, et al.
JAMA Pediatrics|August 16, 2020
Association of Opioid Prescription Initiation During Adolescence and Young Adulthood With Subsequent Substance-Related MorbidityPatrick D Quinn, Kimberly L Fine, Martin E Rickert, et al.
Pediatrics|February 7, 2022
Initiation of Opioid Prescription and Risk of Suicidal Behavior Among Youth and Young AdultsKimberly L Fine, Martin E Rickert, Lauren M O'Reilly, et al.
European Addiction Research|March 7, 2018
International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity DisorderCleo L Crunelle, Wim van den Brink, Franz Moggi, et al.
Psychiatria Hungarica : a Magyar Pszichiatriai Tarsasag Tudomanyos Folyoirata|December 2, 2020
[Recommendations for the screening, diagnosis and treatment of patients with comorbid attention deficit hyperactivity- and substance use disorder]Máté Kapitány-Fövény, Csaba Barta, Cleo L Crunelle, et al.
European Addiction Research|June 30, 2020
The International Collaboration on ADHD and Substance Abuse (ICASA): Mission, Results, and Future ActivitiesGeurt Van de Glind, Christoffer Brynte, Arvid Skutle, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 28, 2026
Polygenic risk scores reveal genetic underpinnings of comorbidity betweensubstance use disorders and ADHDLisa I Horstman, Dora Koller, Judit Cabana-Domínguez, et al.
The International Journal of Social Psychiatry|June 13, 2025
Religiousness and self-control in patients with substance use disorder (SUD) and comorbid attention deficit/hyperactivity disorder (ADHD)Alex Ha Begeman, Arnt Schellekens, Wim van den Brink, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 7, 2026
Predictors of treatment success in patients with substance use disorder (SUD) and co-morbid attention deficit/hyperactivity disorder (ADHD): Results from the International Naturalistic Cohort Study of ADHD and SUD (INCAS)Christoffer Brynte, Arnt Schellekens, Maija Konstenius, et al.
Pageof 13